Impact of population-specific pharmacogenomic variants on drug dosing in ICU patients [0.03%]
特定人群药物基因组变异对ICU患者用药剂量影响的研究
Mahboubeh R Rostami,Juan Rodriguez-Flores,Ali Ait Hssain et al.
Mahboubeh R Rostami et al.
Intensive care units (ICU) patients are highly vulnerable to inaccurate drug dosing. Pharmacogenomics (PGx) studies the role of inherited genetic variation in drug metabolism and dose efficacy. To assess the prevalence of PGx variants that ...
Exploring biomarkers for treatment response in psoriatic arthritis: a focus on multi-omics technologies [0.03%]
探讨银屑病关节炎治疗反应生物标志物：多组学技术聚焦
Moshiur Rahman Khasru,Nahdia Afiifah Abdul Jalil,Nisha Nair et al.
Moshiur Rahman Khasru et al.
Psoriatic arthritis (PsA) is a complex inflammatory disease characterised by a combination of cutaneous and musculoskeletal symptoms, which complicates both diagnosis and management. Despite advances in targeted therapy, the treatment of Ps...
FTO rs7195994 Is associated with TNF inhibitor response in lean rheumatoid arthritis patients: A BMI-stratified pharmacogenetic analysis [0.03%]
BMI分层的药理基因组学分析发现肥胖相关基因FTO多态性与类风湿关节炎患者的肿瘤坏死因子抑制剂疗效有关
Yi-Ting Li,I-Chieh Chen,Hui-Wen Yang et al.
Yi-Ting Li et al.
Tumor necrosis factor inhibitors (TNFi) have transformed the management of rheumatoid arthritis (RA); however, up to 40% of patients fail to achieve an adequate clinical response. Current clinical predictors remain insufficient, highlightin...
CYPRI: a clinical decision-making tool to select psychiatric patients for pharmacogenetic testing [0.03%]
CYPRI：一种临床决策工具 用于选择进行精神药物基因组检测的精神病患者
Ivana Tašková,Nicole Šafářová,Martina Hahn
Ivana Tašková
Pharmacogenetic (PGx) testing of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 is increasingly utilised to personalise psychopharmacological treatment, but clear criteria for patient selection are lacking. We developed and conducted a pi...
Observational Study
The pharmacogenomics journal. 2026 Apr 29;26(3):19. DOI:10.1038/s41397-026-00414-4 2026
The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine [0.03%]
细胞色素P450多态性在口服艾斯 ketamine药代动力学中的作用
Daniël T Coerts,Sanne Y Smith-Apeldoorn,Jérôme C Oude Nijhuis et al.
Daniël T Coerts et al.
Oral esketamine displays therapeutic potential for treatment-resistant depression. However, treatment is complicated by a low and variable bioavailability. Genetic polymorphisms in the cytochrome P450 (CYP) enzymes responsible for esketamin...
Randomized Controlled Trial
The pharmacogenomics journal. 2026 Apr 24;26(3):18. DOI:10.1038/s41397-026-00405-5 2026
Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy [0.03%]
欧洲心脏病学会心血管药理工作组关于药物基因组学的调查问卷——药师态度研究
Emma F Magavern,G-Andrei Dan,Gianluigi Savarese et al.
Emma F Magavern et al.
The aim of this study was to elucidate cardiovascular prescriber access, uptake, and attitudes toward CYP2C19 and CYP2D6 genetic testing to guide prescribing of commonly used medications such as clopidogrel, antiarrhythmics, proton pump inh...
A randomized trial to evaluate attitudes regarding pharmacogenomics among pregnant and pediatric populations: design and baseline characteristics [0.03%]
一项关于孕期和儿科人群药物基因组学态度的随机对照试验的设计及基线特征
Alexandra C Sundermann,Salisha E Marryshow Batson,Elizabeth A Jasper et al.
Alexandra C Sundermann et al.
Pharmacogenomics (PGx) is a key component of precision medicine, yet most PGx studies exclude pregnant people and children. The VICE (Vanderbilt Integrated Center of Excellence)-MPRINT (Maternal and Pediatric Precision in Therapeutics): Mat...
Randomized Controlled Trial
The pharmacogenomics journal. 2026 Apr 23;26(3):16. DOI:10.1038/s41397-026-00413-5 2026
Cost-effectiveness of genotype-guided acenocoumarol therapy in atrial fibrillation: a pharmacogenomic simulation study in the chilean population [0.03%]
基于基因型的乙亩香豆素治疗房颤的成本效益分析：智利人口的药理基因组学仿真研究
Maximiliano Mena,Matías Carrasco,Leslie C Cerpa et al.
Maximiliano Mena et al.
Cardiovascular diseases are the leading cause of death in Chile and worldwide, representing a major public health challenge that demands urgent preventive and therapeutic strategies. In atrial fibrillation, anticoagulation is essential, and...
A pilot study of pharmacogenomic testing as a tool to enhance depression care in Veterans [0.03%]
veterans事务部门中关于药理基因组学检测作为增强抑郁症治疗的工具的试点研究
Kevin P Kennedy,Kevin G Lynch,Ryan Bremseth-Vining et al.
Kevin P Kennedy et al.
Modest outcomes from pharmacogenomic (PGx) testing in depression may be influenced by low rates of actionable gene-drug interactions. This 12-week pilot pragmatic randomized clinical trial evaluated the effectiveness of selectively targetin...
Randomized Controlled Trial
The pharmacogenomics journal. 2026 Apr 14;26(2):14. DOI:10.1038/s41397-026-00406-4 2026
Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study [0.03%]
卡马西平和普瑞巴林联合治疗三叉神经痛的疗效及安全性：随机、双盲临床试验报告
Carolin Görnert,Maike Scherf-Clavel,Heike Weber et al.
Carolin Görnert et al.
Variants in cytochrome P450 enzymes are known risk factors for developing adverse drug reactions (ADR). Most antidepressants (AD) are simultaneously metabolized by major or minor pathway of CYP2C19 and CYP2D6, resulting in a complex interpl...